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ABSTRACT
Substantial resources have been spent to improve pain control for dying patients, and in-
creased opioid administration has been presumed. Oregon has been a consistent leading state
in per capita use for morphine for the past 10 years, as recorded by the Automation of Re-
ports and Consolidated Orders System (ARCOS). Health policy experts, extrapolating from
World Health Organization methods, have suggested these data are indicative of the quality
of end-of-life care in Oregon. To determine whether trends in opioid prescription at the state
and national levels reflect increased opioid use for inpatients during the final week of life,
chart reviews were conducted to record all opioid medications administered in the last week
of life to 877 adult inpatients who died from natural causes between January 1, 1997 and De-
cember 31, 1999. Inpatient morphine use did not increase significantly for dying patients from
1997 to 1999. However, overall morphine use for both Oregon and the United States as mea-
sured by ARCOS data increased significantly. Comparisons revealed no significant differ-
ence between linear trends for Oregon and U.S. morphine use, but both were significantly
greater than the dying inpatients. This pattern was also found for all other opioids. These
findings suggest that ARCOS data do not necessarily provide information about opioid use
for specific subpopulations of patients and raise questions about the meaning of observed
increases in ARCOS data.
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INTRODUCTION
ADEQUATE PAIN MANAGEMENT is vital to qualityend-of-life care.1 Opioid analgesics are a
mainstay in the treatment of moderate to severe
pain for patients who are dying.2 Their efficacy
in managing pain has been demonstrated in con-
trolled studies and meta-analyses in patients with
cancer and other painful conditions, and studies
of the World Health Organization (WHO) cancer
pain treatment protocol confirm that treatment is
effective in as many as 90% of cancer patients.3
However, despite the existence of proven, effica-
cious therapies, many dying patients continue to
experience significant pain.3,4 The SUPPORT
study found that 50% of seriously ill patients hos-
pitalized in five academic medical centers were
reported to be in moderate to severe pain during
the last 3 days of their lives.5
Over the past decade, substantial resources
have been directed toward improving the care of
dying patients, with specific efforts aimed at pain
management. However, measurement of the de-
gree to which these strategies have been effective
in decreasing pain in the dying is challenging.
Trends in total opioid purchasing are one surro-
gate measure of efforts to improve pain manage-
ment. The WHO regards a country’s morphine
purchasing to be an important indicator of the
progress of its worldwide effort to improve can-
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cer pain relief.6 Within the United States, this
thinking has been extrapolated to the state level.
A recent New England Journal of Medicine Health
Policy Report7 favorably characterized palliative
care in Oregon, citing the fact that Oregon ranks
first among the states in medical use of morphine
as one piece of support.
However, it is unclear whether trends in a
state’s total medical opioid use, as reflected by
purchasing data, can be used as an indicator of
efforts to improve end-of-life care. Opioids can be
used for a range of purposes and it is not possi-
ble within existing data to identify how much of
the opioids used are actually administered to 
dying patients. In order to determine whether
trends in opioid use are reflective of pain man-
agement for dying patients, we conducted a chart
review to extract information about the type and
amount of opioids administered to dying hospi-
talized inpatients at an academic medical center
during the last week of life over a 3-year period.
These data were then compared with statewide
and national trends in medical opioid use to bet-
ter understand the relationship between trends in
opioid use and opioid administration to the dying.
METHODS
Setting
Oregon Health & Science University (OHSU)
is an urban, academic hospital with 411 beds.
Since 1995, OHSU has had both a palliative care
team and two pain services. The University has
a diagnostically and geographically diverse pa-
tient population with approximately one third of
all patients referred from outside the Portland
metropolitan area.8
Procedures
After approval from the Institutional Review
Boards at both OHSU and the Oregon Department
of Human Services, OHSU hospital death logs
were used to identify adults who died in the hos-
pital between January 1, 1997 and December 31,
1999. In collaboration with the Oregon Depart-
ment of Human Resources, this information was
used to pull each death certificate. Deaths caused
by accident, homicide, suicide, undetermined
causes under investigation, or in emergency de-
partments were excluded from the sample.
Sample
The OHSU medical records department lo-
cated complete medical records for all but 11 of
the 900 deceased patients. Another 9 patients
were eliminated from the sample because they re-
ceived epidural opioids. Patients given medica-
tion via this route were excluded because there is
no clear consensus on the relative potency of oral
and epidural opioids. Furthermore, as epidural
opioids are from 10 to 100 times more potent than
intravenous medications, the amounts of opioids
excluded from our totals (measured in grams) are
comparatively miniscule.9,10 An additional 3 pa-
tients were eliminated because data were inad-
vertently collected for more than 7 days. This left
a sample of n 5 877, 97.4% of all potentially eli-
gible decedents.
Data sources
OHSU inpatient data. Once each record was lo-
cated, demographic data from the death certificate
were recorded onto a data collection form and the
death certificate was then shredded to protect the
anonymity of the decedent. Patient characteristics
are presented in Table 1. All data collection was
conducted by a clinical pharmacist (J.B.). The ex-
act time of death was used in combination with
the date and time of admission in order to deter-
mine the precise time period included in the chart
review. For patients who died less than a week af-
ter admission to an inpatient unit, opioid data
were recorded for their entire stay. For patients
who died after more than 1 week as an inpatient,
opioid data were recorded for the 7 days (168
hours) prior to death. The total amount of opioid
administered each calendar day was recorded
onto a data collection form and converted indi-
vidually into oral morphine equivalencies.
Oregon and United States medical use data. The
U.S. Drug Enforcement Administration collects
and reports all Schedule II opioids purchased for
medical use by retail pharmacies, hospitals, and
physicians across the United States through the
Automation of Reports and Consolidated Orders
System (ARCOS).11 These data are reported quar-
terly for all opioids used in grams per 100,000
population. Quarterly totals reflect the total
amount of drug in grams without any conver-
sions performed to take formulation (and differ-
ences in potency) into account. This is important
to note because oral/sublingual formulations of
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medications may require higher amounts of med-
ication to achieve the same effect as intrave-
nous/subcutaneous formulations. For example,
30 mg of oral morphine has approximately the
same potency as 10 mg of intravenous morphine.3
However, in the ARCOS data, 300 mg of oral 
morphine and 100 mg of intravenous morphine
would be added together and presented as 400
mg (or 0.4 grams) of morphine used.
Oregon and United States opioid medical use
data from January 1, 1997 to December 31, 1999
were used in the analyses. It should be noted that
opioids used to treat dying hospitalized patients
at OHSU would have been included in overall
use totals as reflected by the United States and
Oregon medical use data. Also, Oregon is one of
the states included in the United States ARCOS
medical use data.
Data analysis
In order to compare pain medication trends over
time, several steps were taken to facilitate com-
parison between these three data sets (OHSU in-
patient use, Oregon medical use, United States
medical use). First, the total number of milligrams
of each opioid administered to OHSU inpatients
was added together by drug, irrespective of for-
mulation, similar to the way that Oregon and
United States medical use data are calculated. This
step was necessary to achieve as similar a unit of
analysis as possible between the three data sets.
Second, opioids in the OHSU inpatient data,
Oregon medical use data, and United States med-
ical use data were converted into oral morphine
equivalencies using an equianalgesic table (Table
2). Because the calculated totals for each drug
were not formulation-specific, the most com-
monly administered formulation (based on OHSU
inpatient data) was assumed in making conver-
sions to oral morphine equivalencies for drugs
available in more than one formulation. Table 2
shows equianalgesic potency conversions and
provides a reference to convert one medication
given by a specific route to the equipotent amount
of another given by the same or different route.
For example, 60 mg of oral morphine is equiva-
lent in potency to 20 mg of parenteral morphine,
15 mg of oral hydromorphone, or 600 mg of oral
meperidine. Similarly, 60 mg of oral morphine
would be equivalent in potency to 3 mg of intra-
venous hydromorphone, or 0.2 mg of parenteral
fentanyl. Methodologic uncertainties surrounding
equianalgesic dosing were minimized by using
the same conversion ratios for each data set.12,13
Third, to compare changes over time in the
three data sets, OHSU inpatient data were con-
verted to grams per 100,000 dying hospitalized
patients, similar to the Oregon and United States
medical use data. The total amount of drugs per
quarter in oral morphine equivalencies was di-
vided by the number of patients per quarter and
multiplied by 100,000 to obtain the total grams
per 100,000 population.
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TABLE 1. INPATIENT DECEDENT CHARACTERISTICS
Year of death 1997 1998 1999
Number of deaths 289 251 337
Average age (in years) 59.1 59.4 59.5
Gender (% female) 49.5% 51.0% 44.2%
Race (% white) 94.4% 89.2% 89.3%
Cause of death
Cancer 15.6% 16.7% 14.2%
Cerebrovascular disease 9.0% 10.4% 16.6%
Heart disease 22.5% 20.3% 19.0%
Liver disease 10.7% 8.4% 8.0%
Pneumonia 8.3% 9.6% 7.1%
Septicemia 17.6% 18.5% 15.1%
Other 16.3% 16.1% 20.0%
Average length of 4.7 5.0 4.6
review period
(in days)a
Patients receiving any 86.9% 90.4% 91.4%
opioid during the final
week of life
aReview period length was capped at a maximum of 7 days.
Statistics. Data were analyzed using SPSS 11.0
(SPSS Inc., Chicago, IL). We were specifically in-
terested in comparing morphine to all other opi-
oids in the study. Using this approach, we were
able to calculate the total amount of morphine (in
oral morphine grams per 100,000 population) and
all other opioids (in oral morphine grams per
100,000 population). After initial inspection of
means, regressions were performed. The slope
was used to assess whether changes over time
were statistically significant in each of the three
data sets. Pairwise R to Z transformations, in
which the regression correlation for each set of
data serves as the basis of comparison, were used
to determine whether the linear trends for each
data set were significantly different from each
other.14 The regression correlation was used as the
basis of comparison rather than the slope, because
slopes are affected by the standard error while re-
gression correlations are not. The awas set at p ,
0.05 for these analyses. The opioids included in
this study were morphine, fentanyl, hydromor-
phone, meperidine, methadone, oxycodone, and
sufentanil. Alfentanil, tramadol, and propoxy-
phene were excluded from analyses because each
drug was administered to fewer than four OHSU
inpatients over the 3-year study period.
RESULTS
Regressions were performed on the OHSU in-
patient, Oregon, and United States morphine use
data with time period (n 5 12 quarters) as the in-
dependent variable and average grams per
100,000 population as the dependent variable.
OHSU inpatient morphine use did not increase
significantly from 1997 to 1999 (b 5 0.139, p 5
0.666). However, statewide Oregon morphine use
did increase significantly between 1997 and 1999
(b5 0.837, p5 0.001) as did United States mor-
phine use (b5 0.885, p , 0.001).
Analysis indicated that the linear trend for
OHSU inpatient use of morphine was signifi-
cantly different from both Oregon morphine use
(z 5 22.27, p 5 0.011) and United States mor-
phine use (z 522.68, p5 0.003). This suggests that
morphine use in the United States and Oregon
were increasing at significantly greater rates than
OHSU inpatient use during the final week of life.
However, the Oregon and United States morphine
linear trends were not significantly different from
each other (z5 0.41, p5 0.35), suggesting that the
increased rate of change in morphine use was sim-
ilar in Oregon and the United States.
Linear trends for morphine use are graphically
displayed by quarter over the 3-year period in
Figure 1. Standard units were used because, as
expected, the grams of morphine per 100,000 pop-
ulation were very different for the OHSU inpa-
tient data (average for first quarter of 1997 5 1816
grams per 100,000 population) as compared to the
statewide Oregon (average first quarter of 1997 5
690 grams per 100,000 population) and United
States data (average first quarter of 1997 5 494
grams per 100,000 population). In order to aid in
interpretation, the standardized values were cen-
tered on time 1.
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TABLE 2. EQUIANALGESIC POTENCY CONVERSION CHART
Opioid IM/IV dose Oral dose
Fentanyl22 0.10 N/A
Hydromorphone3 1.50 7.5
Meperidine22 75.00 300.0
Methadone3 10.00 20.0
Morphine3 10.00 30.0
Oxycodone3 N/A 30.0
Sufentanil3 0.02 N/A
Fentanyl patch conversions23
Fentanyl patch delivery Morphine oral equivalent Morphine parenteral
(in mcg/hr) (mg/24 hr) equivalent
(mg/24 hr)
25 45–134 (,90) 8–22 (,15)
50 135–224 (,180) 23–37 (,30)
75 225–314 (,270) 38–52 (,45)
100 315–404 (,360) 53–67 (,60)
Multiples of the above fentanyl increments could be used to find the appropriate morphine dose or vice versa
IM, intramuscular; IV, intravenous.
Regressions were also performed with all other
opioids in the study (fentanyl, hydromorphone,
hydrocodone, meperidine, methadone, oxycodone,
and sufentanil) in oral morphine equivalency as
the dependent variable and time period (n 5 12
quarters) as the independent variable. There was
no significant change in the amount of other opi-
oids administered to dying OHSU inpatients
over the 3 years (b 5 0.161, p 5 0.616), although
there was a nonsignificant upward trend over
time. As with the morphine data, there was also
a significant increase over time in the amount of
other opioids used in Oregon (b 5 0.957, p ,
0.001) and in the United States (b 5 0.991, p ,
0.001).
Analysis indicates that the linear trend for
OHSU inpatient use of other opioids was signif-
icantly different from the linear trends for both
Oregon use of other opioids (z 5 23.8, p , 0.001)
and United States use of other opioids (z 5 25.3,
p , 0.001). However, there was no difference be-
tween the linear trends for Oregon use of opioids
and United States use of opioids (z 5 21.5, p 5
0.07). Thus, overall medical use of opioids in-
creased over the 3-year period in Oregon and the
United States but remained stable at OHSU.
Linear trends for opioids are graphically dis-
played in Figure 2. Standard units were used be-
cause, as expected, the grams per 100,000 popu-
lation were very different for the hospital data
(e.g., average for first quarter of 1997 5 85,895 g
per 100,000 population) compared to the Oregon
(average first quarter of 1997 5 2420 g per 100,000
population) and United States data (average first
quarter of 1997 5 2323 g per 100,000 population).
In order to aid in interpretation, the standardized
values were centered on time 1.
DISCUSSION
Morphine use increased significantly in Ore-
gon and the United States from 1997 to 1999.
However, there was no significant increase in the
amount of morphine administered to dying in-
patients in our sample. The stable use of mor-
phine could not be accounted for by a switch to
other opioid agents, because like morphine, the
trend for other opioids administered to dying in-
patients was also relatively flat despite significant
increases in use reflected in US and Oregon AR-
COS data.
Why is statewide Oregon use of opioids in-
creasing while opioid use for dying inpatients at
an Oregon hospital is not? It is possible that in-
creasing state opioid use reflects increased pre-
scriptions to other patient populations, such as
those with chronic pain or postsurgical patients.
Another possibility is increasing diversion, though
a study in Wisconsin between 1986 and 1990 found
no evidence of increased diversion despite in-
creases in morphine of 160% during that time pe-
riod.6 It is also possible that the inpatients in this
sample were already receiving aggressive pain
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FIG. 1. Standardized regression coefficients reflecting the use of morphine for Oregon Health & Science University
(OHSU) inpatients, Oregon, and the United States from 1997–1999.
management and receiving the maximally neces-
sary amounts of opioids. Self-reports by Oregon
physicians indicate many were spurred into ac-
tion in part by the 1994 vote to legalize physician-
assisted suicide and voluntarily sought classes to
improve their palliative care skills before the time
period covered in this survey.15
Alternatively, dying inpatients may not be ben-
efiting from increased statewide medical use of
opioids because of the effects on prescribing of a
complex political environment in Oregon sur-
rounding end-of-life care issues.16 In one survey
of recently bereaved Oregon family members,
family reports of moderate and severe pain in-
creased in late 1997, following a second vote to
legalize physician-assisted suicide.17 When
physicians and nurses were asked to explain the
increase in family reports of pain, suggested rea-
sons included increased family awareness of pain
(endorsed by 96%), decreased physician pre-
scribing of opioids (endorsed by 66%), and de-
creased nurse administration of opioids (en-
dorsed by 57%). Fears of investigation were the
most commonly cited reasons for decreased pre-
scribing and administration.18 Although Oregon
had a historical reputation for aggressive inves-
tigation of over prescription of opioids, the Ore-
gon Board of Medical Examiners announced its
intent to investigate the under-treatment of pain
as aggressively as the over-treatment of pain in
1998.19
Regardless of the reasons for the discrepancy
between an academic hospital and ARCOS data,
these findings suggest that the ARCOS data alone
do not provide adequate information about pain
trends for specific patient populations. This is not
surprising given that the ARCOS system was de-
signed to monitor the legitimate distribution of
controlled substances, not to assess the quality of
clinical care.20 The ARCOS data contains the to-
tal amount of opioids purchased by pharmacies
and hospitals, not necessarily actual use by spe-
cific patient populations.11
The study has limitations that are important to
note. First, the data on opioids administered to
dying patients are from a single urban academic
acute care health center in one state. There are no
comparable data available about trends in opioid
use in the final week of life for those dying in
other hospitals or in community settings. This is
particularly relevant in Oregon, which has among
the lowest in-hospital death rates in the country.21
It is possible that changes occurred in opioid ad-
ministration to those dying at home and in long-
term care facilities but not in the hospital where
this study was conducted. These limitations af-
fect the generalizability of findings. Second, the
3-year time frame may have limited the ability to
identify changes in this single hospital that might
be detectable over a longer time period. Third, in
order to compare trends over time, state and na-
tional medical use data were compared to inpa-
tient administration data. Changes were made to
make these data sets as similar as possible, but
this cannot change the fact that the data measure
different (though related) constructs.
TOLLE ET AL.44
S
ta
nd
ar
di
ze
d 
op
io
id
 u
ni
ts 3
2.5
3.5
2
1.5
1
0.5
0
1 2 3 4 5 6 7
Time period (in quarters)
8 9 10 11 12
Oregon Opioid Use
OHSU Inpatient Opioid Use
United States Opioid Use
FIG. 2. Standardized regression coefficients reflecting the use of fentanyl, hydromorphone, meperidine, oxycodone,
sufentanil, and methadone for Oregon Health & Science University (OHSU) inpatients, Oregon, and the United States
from 1997–1999.
This 3-year study found opioid use to be un-
changed in a population of dying hospitalized pa-
tients despite increases in national and state use
of opioids. It is unclear which patient populations
are receiving increases in opioid use. However, it
is clear that trends in ARCOS data cannot be pre-
sumed to apply equally to all patient groups. Fur-
ther research is needed to better measure and un-
derstand trends in opioid use for dying patients.
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